Madrigal price target raised to $400 from $390 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $400 from $390 and keeps a Buy rating on the shares. The company reported Rezdiffra net sequential sales growth at least 61% over Q3, the analyst tells investors in a research note. In 2025, the firm looks to tw factors that could further propel Rezdiffra’s sales contribution: U.S. payor coverage for Rezdiffra increasing above the “more than 80%” of commercial lives achieved as of September 30, and Rezdiffra’s anticipated expansion into Europe in the second half of the year.